Cited by 744Acute Myeloid Leukemia ResearchGlioma Diagnosis and TreatmentCancer, Hypoxia, and Metabolism

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

Open access

Gross, Stefan, Cairns, Rob A., Minden, Mark D., Driggers, Edward M., Bittinger, Mark A., Jang, Hyun Gyung, Sasaki, Masato, Jin, Shengfang, Schenkein, David P., Su, Shinsan M., Dang, Lenny, Fantin, Valeria R., Mak, Tak W.·2010·Journal of Experimental Medicine

DOI 10.1084/jem.20092506PMC PMC2822606

Open this paper in CoChat — free account Open PDF

Abstract

Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), are present in most gliomas and secondary glioblastomas, but are rare in other neoplasms. IDH1/2 mutations are heterozygous, and affect a single arginine residue. Recently, IDH1 mutations were identified in 8% of acute myelogenous leukemia (AML) patients. A glioma study revealed that IDH1 mutations cause a gain-of-function, resulting in the production and accumulation of 2-hydroxyglutarate (2-HG). Genotyping of 145 AML biopsies identified 11 IDH1 R132 mutant samples. Liquid chromatography-mass spectrometry metabolite screening revealed increased 2-HG levels in IDH1 R132 mutant cells and sera, and uncovered two IDH2 R172K mutations. IDH1/2 mutations were associated with normal karyotypes. Recombinant IDH1 R132C and IDH2 R172K proteins catalyze the novel nicotinamide adenine dinucleotide phosphate (NADPH)–dependent reduction of α-ketoglutarate (α-KG) to 2-HG. The IDH1 R132C mutation commonly found in AML reduces the affinity for isocitrate, and increases the affinity for NADPH and α-KG. This prevents the oxidative decarboxylation of isocitrate to α-KG, and facilitates the conversion of α-KG to 2-HG. IDH1/2 mutations confer an enzymatic gain of function that dramatically increases 2-HG in AML. This provides an explanation for the heterozygous acquisition of these mutations during tumorigenesis. 2-HG is a tractable metabolic biomarker of mutant IDH1/2 enzyme activity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1084/jem.20092506

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citation
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
Hartmann, C. J., Meyer, J., Balß, J., Capper, D., Mueller, W. C., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Sanson, M., Marie, Y., Paris, S., Idbaïh, A., Laffaire, J., Ducray, F., Hallani, S. E., Boisselier, B., Mokhtari, K., Hoang‐Xuan, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9832 · Cited by 1,049
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027
Chaperone Coexpression Plasmids: Differential and Synergistic Roles of DnaK-DnaJ-GrpE and GroEL-GroES in Assisting Folding of an Allergen of Japanese Cedar Pollen, Cryj2, in Escherichia coli
Nishihara, K., Kanemori, M., Kitagawa, M., Yanagi, H., & Yura, T. (1998) · Applied and Environmental Microbiology · doi:10.1128/aem.64.5.1694-1699.1998 · Cited by 440

Flagged first, then by citations

Show all 23 references

Sorted by citations

Items 301–400 of 744

Development and Maintenance of Cancer Stem Cells under Chronic Inflammation
Tanno, T., & Matsui, W. H. (2011) · Journal of Nippon Medical School · doi:10.1272/jnms.78.138 · Cited by 39
From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?
Bewersdorf, J. P., Ardasheva, A., Podoltsev, N. A., Singh, A., Biancon, G., Halene, S., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100587 · Cited by 37
Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells
Gerecke, C., Schumacher, F., Berndzen, A., Homann, T., & Kleuser, B. (2019) · Epigenetics · doi:10.1080/15592294.2019.1666652 · Cited by 36
The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms
Schaefer, I., Hornick, J. L., & Bovée, J. V. M. G. (2018) · Laboratory Investigation · doi:10.1038/s41374-017-0003-6 · Cited by 36
Mutant IDH1 is required for IDH1 mutated tumor cell growth
Jin, G., Pirozzi, C. J., Chen, L. H., Lopez, G. Y., Duncan, C. G., Feng, J., Spasojević, I., Bigner, D. D., He, Y., & Yan, H. (2012) · Oncotarget · doi:10.18632/oncotarget.577 · Cited by 37
Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective
Ma, T., Zou, F., Pusch, S., Xu, Y., von Deimling, A., & Zha, X. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00159 · Cited by 35
The Time Has Come for Targeted Therapies for AML: Lights and Shadows
Fiorentini, A., Capelli, D., Saraceni, F., Menotti, D., Poloni, A., & Olivieri, A. (2020) · Oncology and Therapy · doi:10.1007/s40487-019-00108-x · Cited by 35
Take Advantage of Glutamine Anaplerosis, the Kernel of the Metabolic Rewiring in Malignant Gliomas
Martins, F., Gonçalves, L. G., Pojo, M., & Serpa, J. (2020) · Biomolecules · doi:10.3390/biom10101370 · Cited by 35
How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?
Patel, J. P., & Levine, R. L. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.28.3797923 · Cited by 37
Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate
Rakheja, D., Boriack, R. L., Mitui, M., Khokhar, S., Holt, S. A., & Kapur, P. (2010) · Tumor Biology · doi:10.1007/s13277-010-0125-6 · Cited by 37
Pivotal Role of Pervasive Neoplastic and Stromal Cells Reprogramming in Circulating Tumor Cells Dissemination and Metastatic Colonization
Meseure, D., Alsibai, K. D., & Nicolas, A. (2014) · Cancer Microenvironment · doi:10.1007/s12307-014-0158-2 · Cited by 36
IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?
Petrová, L., Vrbacký, F., Lánská, M., Zavřelová, A., Зак, П., & Hrochová, K. (2018) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.08.012 · Cited by 35
Unraveling the mystery of cancer metabolism in the genesis of tumor-initiating cells and development of cancer
Zhang, G., Yang, P., Guo, P.-D., Miele, L., Sarkar, F. H., Wang, Z. P., & Zhou, Q. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.03.001 · Cited by 34
Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?
Kundranda, M. N., Tibes, R., & Mesa, R. A. (2011) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-011-0107-9 · Cited by 34
Decoding key nodes in the metabolism of cancer cells: sugar & spice and all things nice
Cantley, L., & Shaw, R. (2011) · F1000 Biology Reports · doi:10.3410/b4-2 · Cited by 34
Olutasidenib: from bench to bedside
Venugopal, S., & Watts, J. M. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009854 · Cited by 34
PII Protein-Derived FRET Sensors for Quantification and Live-Cell Imaging of 2-Oxoglutarate
Lüddecke, J., Francois, L., Spät, P., Watzer, B., Chilczuk, T., Poschet, G., Hell, R., Radlwimmer, B., & Forchhammer, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-01440-w · Cited by 35
Isocitrate dehydrogenase 1 and 2 mutations, 2‐hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia
Brunner, A. M., Neuberg, D. S., Wander, S. A., Sadrzadeh, H., Ballen, K. K., Amrein, P. C., Attar, E. C., Hobbs, G. S., Chen, Y., Perry, A. M., et al. (2018) · Cancer · doi:10.1002/cncr.31729 · Cited by 35
Integration of hypoxic HIF-α signaling in blood cancers
Schito, L., Rey, S., & Konopleva, M. Y. (2017) · Oncogene · doi:10.1038/onc.2017.119 · Cited by 34
Comprehensive Metabolomic Analysis of IDH1R132H Clinical Glioma Samples Reveals Suppression of β-oxidation Due to Carnitine Deficiency
Miyata, S., Tominaga, K., Sakashita, E., Urabe, M., Onuki, Y., Gomi, A., Yamaguchi, T., Mieno, M., Mizukami, H., Kume, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46217-5 · Cited by 33
Dietary Alpha‐Ketoglutarate Promotes Epithelial Metabolic Transition and Protects against DSS‐Induced Colitis
Tian, Q., Iniguez, A. B., Sun, Q., Wang, H., Du, ‬., & Zhu, M. J. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000936 · Cited by 33
New Therapeutic Strategies for Adult Acute Myeloid Leukemia
Ishii, H., & Yano, S. (2022) · Cancers · doi:10.3390/cancers14112806 · Cited by 33
Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Liu, A. C. H., Cathelin, S., Yang, Y., Dai, D. L., Ayyathan, D. M., Hosseini, M., Minden, M. D., Tierens, A. M., & Chan, S. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1293 · Cited by 33
Self-citation
Molecular subtypes of glioma identified by genome‐wide methylation profiling
Kloosterhof, N. K., de Rooi, J. J., Kros, M., Eilers, P. H. C., Smitt, P. A. E. S., van den Bent, M. J., & French, P. J. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22062 · Cited by 35
Altered Mitochondrial Signalling and Metabolism in Cancer
Chattopadhyay, E., & Roy, B. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00043 · Cited by 36
Regulative Roles of Metabolic Plasticity Caused by Mitochondrial Oxidative Phosphorylation and Glycolysis on the Initiation and Progression of Tumorigenesis
Niu, N., Ye, J., Hu, Z., Zhang, J., & Wang, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087076 · Cited by 34
Differential Activity of NADPH-Producing Dehydrogenases Renders Rodents Unsuitable Models to Study IDH1 R132 Mutation Effects in Human Glioblastoma
Atai, N. A., Renkema-Mills, N. A., Bosman, J., Schmidt, N., Rijkeboer, D., Tigchelaar, W., Bosch, K. S., Troost, D., Jonker, A., Bleeker, F. E., et al. (2011) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411400606 · Cited by 32
Molecular Evaluation of DNMT3A and IDH1/2 Gene Mutation: Frequency, Distribution Pattern and Associations with Additional Molecular Markers in Normal Karyotype Indian Acute Myeloid Leukemia Patients
Ahmad, F., Mohota, R., Sanap, S., Mandava, S., & Das, B. R. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.3.1247 · Cited by 33
Chiral separation of 2-hydroxyglutaric acid on cinchonan carbamate based weak chiral anion exchangers by high-performance liquid chromatography
Calderón, C., Horak, J., & Lämmerhofer, M. (2016) · Journal of Chromatography A · doi:10.1016/j.chroma.2016.05.042 · Cited by 32
The metabolomic signature of hematologic malignancies
Allegra, A., Innao, V., Gerace, D. G., Bianco, O., & Musolino, C. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.08.002 · Cited by 32
Structure, substrate specificity, and catalytic mechanism of human D-2-HGDH and insights into pathogenicity of disease-associated mutations
Yang, J., Zhu, H., Zhang, T., & Ding, J. (2021) · Cell Discovery · doi:10.1038/s41421-020-00227-0 · Cited by 32
Tumor Microenvironment-Derived Metabolites: A Guide to Find New Metabolic Therapeutic Targets and Biomarkers
García‐Cañaveras, J. C., & Lahoz, A. (2021) · Cancers · doi:10.3390/cancers13133230 · Cited by 33
Biochemistry of the hypoxia-inducible factor hydroxylases
Fiorini, G., & Schofield, C. J. (2024) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2024.102428 · Cited by 33
IDH1 and IDH2 mutations in myeloid neoplasms - Novel paradigms and clinical implications
Cazzola, M. (2010) · Haematologica · doi:10.3324/haematol.2010.030015 · Cited by 32
Isocitrate dehydrogenase 1/2 mutational analyses and 2‐hydroxyglutarate measurements in Wilms tumors
Rakheja, D., Mitui, M., Boriack, R. L., & DeBerardinis, R. J. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22697 · Cited by 33
Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors
Chitneni, S. K., Reitman, Z. J., Spicehandler, R., Gooden, D. M., Yan, H., & Zalutsky, M. R. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.01.015 · Cited by 32
Molecular markers in acute myeloid leukaemia
Kühnl, A., & Grimwade, D. J. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1123-9 · Cited by 33
Mutations in epigenetic regulators in myelodysplastic syndromes
Nikoloski, G., van der Reijden, B. A., & Jansen, J. H. (2012) · International Journal of Hematology · doi:10.1007/s12185-011-0996-3 · Cited by 32
Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia
Koszarska, M., Bors, A., Feczko, A., Meggyesi, N., Bátai, Á., Csomor, J., Ádám, E., Kozma, A., Orbán, T. I., Lovas, N., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.736981 · Cited by 32
Exploring Metabolic Profile Differences between Colorectal Polyp Patients and Controls Using Seemingly Unrelated Regression
Chen, C., Deng, L., Wei, S., Gowda, G. A. N., Gu, H., Chiorean, E. G., Zaid, M. I. A., Harrison, M. L., Pekny, J. F., Loehrer, P. J., et al. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00059 · Cited by 31
Neomorphic mutations create therapeutic challenges in cancer
Takiar, V., Ip, C. K. M., Gao, M., Mills, G. B., & Cheung, L. W. T. (2016) · Oncogene · doi:10.1038/onc.2016.312 · Cited by 33
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer
Chen, D., Xia, S., Wang, M., Lin, R., Li, Y., Mao, H. Z., Aguiar, M., Famulare, C. A., Shih, A. H., Brennan, C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1040 · Cited by 34
Sphingolipid Pathway as a Source of Vulnerability in IDH1mut Glioma
Dowdy, T., Zhang, L., Celiku, O., Movva, S., Lita, A., Ruiz‐Rodado, V., Gilbert, M. R., & Larion, M. (2020) · Cancers · doi:10.3390/cancers12102910 · Cited by 31
Discovery and Optimization of 2H-1λ2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer
Rohde, J. M., Surendra, K., Pragani, R., Liu, L., Fang, Y., Zhang, W., McIver, A. L., Zheng, H., Liu, Q., Davis, M. I., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00019 · Cited by 31
Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1
Liu, S., Abboud, M. I., John, T., Mikhailov, V. A., Hvinden, I. C., Walsby-Tickle, J., Liu, X., Pettinati, I., Cadoux-Hudson, T. A. D., McCullagh, J., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02743-5 · Cited by 31
2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies
Raimondi, V., Ciotti, G., Gottardi, M., & Ciccarese, F. (2022) · Biomedicines · doi:10.3390/biomedicines10061359 · Cited by 35
Contemporary outcomes in IDH ‐mutated acute myeloid leukemia: The impact of co‐occurring NPM1 mutations and venetoclax‐based treatment
Lachowiez, C. A., Reville, P. K., Kantarjian, H. M., Jabbour, E. J., Borthakur, G. M., Daver, N. G., Issa, G. C., Furudate, K., Tanaka, T. N., Pierce, S. A., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26694 · Cited by 31
Survival of the fittest: metabolic adaptations in cancer
Berardi, M. J., & Fantin, V. R. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.001 · Cited by 30
Self-citation
MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome
Qiu, Z., Lin, A., Jiang, S., Elkashef, S. M., Myers, J., Srikantan, S., Sasi, B. K., Cao, J. Z., Godley, L. A., Rakheja, D., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.02.002 · Cited by 31
Cytosolic GDH1 degradation restricts protein synthesis to sustain tumor cell survival following amino acid deprivation
Shao, J., Shi, T., Yu, H. T., Ding, Y., Li, L., Wang, X., & Wang, X. (2021) · The EMBO Journal · doi:10.15252/embj.2020107480 · Cited by 30
Genetic alterations in chondrosarcomas – keys to targeted therapies?
Samuel, A. M., Costa, J. C., & Lindskog, D. M. (2014) · Cellular Oncology · doi:10.1007/s13402-014-0166-8 · Cited by 35
IDH1 Mutations in Oligodendroglial Tumors: Comparative Analysis of Direct Sequencing, Pyrosequencing, Immunohistochemistry, Nested PCR and PNA ‐Mediated Clamping PCR
Lee, D., Suh, Y., Kang, S. Y., Park, T. I., Jeong, J. Y., & Kim, S. H. (2012) · Brain Pathology · doi:10.1111/bpa.12000 · Cited by 30
Precision medicine in myeloid malignancies
Westermann, J., & Bullinger, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.034 · Cited by 29
Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila
Reitman, Z. J., Sinenko, S. A., Spana, E. P., & Yan, H. (2014) · Blood · doi:10.1182/blood-2014-05-577940 · Cited by 29
IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53
Jiang, B., Zhao, W., Shi, M., Zhang, J., Chen, A., Ma, H., Suleman, M., Lin, F., Zhou, L., Wang, J., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001385 · Cited by 29
Rationale design of novel substituted 1,3,5-triazine candidates as dual IDH1(R132H)/ IDH2(R140Q) inhibitors with high selectivity against acute myeloid leukemia: In vitro and in vivo preclinical investigations
Tawfik, H. O., Mousa, M. H. A., Zaky, M. Y., El‐Dessouki, A. M., Sharaky, M. M., Abdullah, O., El‐Hamamsy, M. H., & Al-Karmalawy, A. A. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107483 · Cited by 28
Enigmas of IDH mutations in hematology/oncology
Heuser, M., Cruz, M. M. A., Goparaju, R., & Chaturvedi, A. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.005 · Cited by 28
The Multifaceted Metabolism of Glioblastoma
Quinones, A., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_4 · Cited by 28
IDH1 and IDH2 have critical roles in 2-hydroxyglutarate production in D-2-hydroxyglutarate dehydrogenase depleted cells
Matsunaga, H., Futakuchi-Tsuchida, A., Takahashi, M., ISHIKAWA, T., Tsuji, M., & Ando, O. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.06.002 · Cited by 28
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation
Fan, B., Dai, D., Dinardo, C. D., Stein, E. M., de Botton, S., Attar, E. C., Liu, H., Liu, G., Lemieux, I. R., Agresta, S. V., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04064-6 · Cited by 28
Functions of idh1 and its mutation in the regulation of developmental hematopoiesis in zebrafish
Shi, X. E., He, A. B.-L., Ma, A. C. H., Guo, Y., Chi, Y., Man, C. H., Zhang, W., Zhang, Y., Wen, Z., Cheng, T., et al. (2015) · Blood · doi:10.1182/blood-2014-09-601187 · Cited by 27
Tissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas
Sim, H., Nejad, R., Zhang, W., Nassiri, F., Mason, W. P., Aldape, K., Zadeh, G. M., & Chen, E. X. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3205 · Cited by 27
Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms
Keßler, J., Hohmann, T., Güttler, A., Petrenko, M., Ostheimer, C., Hohmann, U., Bache, M., Dehghani, F., & Vordermark, D. (2019) · Cancers · doi:10.3390/cancers11060889 · Cited by 28
Macrocyclization strategy for improving candidate profiles in medicinal chemistry
Darlami, O., Pun, R., Ahn, S., Kim, S., & Shin, D. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116501 · Cited by 28
Targeting the Metabolic Paradigms in Cancer and Diabetes
Bosso, M., Haddad, D., Madhoun, A. S. A., & Al‐Mulla, F. (2024) · Biomedicines · doi:10.3390/biomedicines12010211 · Cited by 26
JAK-Mutant Myeloproliferative Neoplasms
Levine, R. L. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_170 · Cited by 27
Functions of TET Proteins in Hematopoietic Transformation
Han, J., An, J., & Ko, M. (2015) · Molecules and Cells · doi:10.14348/molcells.2015.0294 · Cited by 26
Isocitrate Dehydrogenase 2 Suppresses the Invasion of Hepatocellular Carcinoma Cells via Matrix Metalloproteinase 9
Tian, G., Zang, S., Wang, L., Luo, Y., Shi, J., & Lou, G. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000438593 · Cited by 26
Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q
Chen, J., Yang, J., Sun, X., Wang, Z., Cheng, X., Lu, W., Cai, X., Hu, C., Shen, X., & Cao, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-16427-w · Cited by 29
Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias
Testa, U., Castelli, G., & Pelosi, E. (2020) · Cancers · doi:10.3390/cancers12092427 · Cited by 26
Mutant IDH : A Targetable Driver of Leukemic Phenotypes Linking Metabolism, Epigenetics and Transcriptional Regulation
Garrett-Bakelman, F. E., & Melnick, A. M. (2016) · Epigenomics · doi:10.2217/epi-2016-0008 · Cited by 25
IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1α
Semukunzi, H., Roy, D., Li, H., Khan, G. J., Lyu, X., Yuan, S., & Lin, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.02.083 · Cited by 25
Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults
Olar, A., Raghunathan, A., Albarracin, C. T., Aldape, K., Cahill, D. P., Powell, S. Z.-E., Goodman, J. C., & Fuller, G. N. (2011) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2011.08.010 · Cited by 25
The Multifaceted Glioblastoma: From Genomic Alterations to Metabolic Adaptations
Quinones, A., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_4 · Cited by 25
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells
Chen, D., Xia, S., Zhang, R., Li, Y., Famulare, C. A., Fan, H., Wu, R., Wang, M., Zhu, A. C., Elf, S., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.06.027 · Cited by 25
Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia
Cathelin, S., Sharon, D. M., Subedi, A., Cojocari, D., Phillips, D. C., Leverson, J. D., MacBeth, K. J., Nicolay, B., Narayanaswamy, R., Ronseaux, S., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01468-y · Cited by 24
Systemic Therapy for Chondrosarcoma
Rock, A. G., Ali, S., & Chow, W. A. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00951-7 · Cited by 25
Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation
Valadez, J. G., Grover, V. K., Carter, M. D., Calcutt, M. W., Abiria, S. A., Lundberg, C. J., Williams, T. V., & Cooper, M. K. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.10.002 · Cited by 24
Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia
Balss, J., Thiede, C., Bochtler, T., Okun, J. G., Saadati, M., Benner, A., Pusch, S., Ehninger, G., Schaich, M. A., Ho, A. D., et al. (2015) · Leukemia · doi:10.1038/leu.2015.317 · Cited by 24
Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
Fiehn, O., Showalter, M. R., Tooley, C. E. S., & Reproducibility Project: Cancer Biology (2016) · eLife · doi:10.7554/elife.12626 · Cited by 24
Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects
Prakash, C., Fan, B., Altaf, S. A., Agresta, S., Liu, H., & Yang, H. Q. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03793-7 · Cited by 24
Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production
Kotredes, K. P., Razmpour, R., Lutton, E. M., Alfonso‐Prieto, M., Ramirez, S. H., & Gamero, A. M. (2019) · Oncotarget · doi:10.18632/oncotarget.26848 · Cited by 24
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
Tap, W. D., Cote, G. M., Burris, H. A., Gore, L., ELIAS, A. D., Beeram, M., Conley, A. P., Gianolio, D. A., Qu, Z., Pandya, S. S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-4128 · Cited by 23
Host genomic influences on HIV/AIDS
O’Brien, S. J., & Hendrickson, S. L. (2013) · Genome biology · doi:10.1186/gb-2013-14-1-201 · Cited by 28
IDHmutations: new genetic signatures in cholangiocarcinoma and therapeutic implications
Borger, D. R., & Zhu, A. X. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.32 · Cited by 23
Lactate dehydrogenase C is required for the protein expression of a sperm-specific isoform of lactate dehydrogenase A
Dodo, M., Kitamura, H., Shima, H., Saigusa, D., Wati, S. M., Ota, N., Katsuoka, F., Chiba, H., Okae, H., Arima, T., et al. (2018) · The Journal of Biochemistry · doi:10.1093/jb/mvy108 · Cited by 24
IDH1-R132 changes vary according to NPM1 and other mutations status in AML
Falini, B., Spinelli, O., Meggendorfer, M., Martelli, M. P., Bigerna, B., Ascani, S., Stein, H., Rambaldi, A., & Haferlach, T. (2019) · Leukemia · doi:10.1038/s41375-018-0299-2 · Cited by 23
In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site
Chaturvedi, A., Goparaju, R., Gupta, C., Weder, J., Klünemann, T., Cruz, M. M. A., Kloos, A., Görlich, K., Schottmann, R., Othman, B., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0582-x · Cited by 25
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
Lyu, J., Liu, Y., Gong, L., Chen, M., Madanat, Y. F., Zhang, Y., Cai, F., Gu, Z., Cao, H., Kaphle, P., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1661 · Cited by 23
The genetics of myelodysplastic syndromes and the opportunities for tailored treatments
Kontandreopoulou, C., Kalopisis, K., Viniou, N., & Diamantopoulos, P. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.989483 · Cited by 23
L-2hydroxyglutaric acid rewires amino acid metabolism in colorectal cancer via the mTOR-ATF4 axis
Tabata, S., Kojima, Y., Sakamoto, T., Igarashi, K., Umetsu, K., Ishikawa, T., Hirayama, A., Kajino‐Sakamoto, R., Sakamoto, N., Yasumoto, K., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02632-7 · Cited by 24
Cancer genomics identifies determinants of tumor biology
Mardis, E. R. (2010) · Genome biology · doi:10.1186/gb-2010-11-5-211 · Cited by 22
Mutation and expression analysis of the IDH1, IDH2, DNMT3A, and MYD88 genes in colorectal cancer
Li, W., Xiao, M., Zhang, D., Yu, D., Yang, R., Li, X., & Yao, Y. (2014) · Gene · doi:10.1016/j.gene.2014.05.070 · Cited by 23
Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype
Virijević, M., Karan-Djurašević, T., Marjanović, I., Tos̆ić, N., Mitrović, M., Đjunić, I., Čolović, N., Vidović, A., Suvajdžić, N., Tomin, D., et al. (2016) · Radiology and Oncology · doi:10.1515/raon-2016-0044 · Cited by 22
Chiral separation of disease biomarkers with 2‐hydroxycarboxylic acid structure
Calderón, C., Santi, C., & Lämmerhofer, M. (2017) · Journal of Separation Science · doi:10.1002/jssc.201701243 · Cited by 22
Pathology of the Tumors of the Central Nervous System
Bumci, R., Parthymos, I., Zamboglou, C., & GOUSSIA, A. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-33517-4_6 · Cited by 22
Epigenetic Mechanisms in Leukemias and LymphomasPreprint
Duy, C., Béguelin, W., & Melnick, A. M. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034959 · Cited by 23
Pharmacological characterization of TQ 05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants
Gao, M., Zhu, H., Li, F., Li, Y., Bao, X., Fu, H., Quan, H., Wang, L., & Lou, L. (2019) · Cancer Science · doi:10.1111/cas.14152 · Cited by 21
A double surrogate approach for the quantitation of 2-Hydroxyglutarate – An oncometabolite in human brain tumors via LC-MS/MS
Yin, F. Q., Keller, J., Kraus, D. H., Mangus, H., Li, F., & Liu, G. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.112916 · Cited by 21
Measurement of 2-hydroxyglutarate enantiomers in serum by chiral gas chromatography-tandem mass spectrometry and its application as a biomarker for IDH mutant gliomas
Strain, S. K., Groves, M. D., Olino, K. L., & Emmett, M. R. (2019) · Clinical mass spectrometry · doi:10.1016/j.clinms.2019.11.002 · Cited by 21

Authors: Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., Dang, L., Fantin, V. R., & Mak, T. W.
Affiliations: Agios Pharmaceuticals Incorporated, Cambridge, MA 02139 1
University Health Network (CA)
Agios Pharmaceuticals (United States) (US)
Corresponding author: Fantin, Valeria R.
Mak, Tak W.
ORCID: Cairns, Rob A.
Minden, Mark D.
Jang, Hyun Gyung
Sasaki, Masato
Dang, Lenny
Fantin, Valeria R.
Mak, Tak W.
Venue: Journal of Experimental Medicine
Publisher: Rockefeller University Press
Published: 2010-02-08
Volume: 207
Issue: 2
Pages: 339-344
ISSN: 0022-1007 (ISSN-L)
1540-9538
DOI: 10.1084/jem.20092506
PMC: PMC2822606
OpenAlex: W2159731673
Cited by: 736
References: 23
Citations by year: 2026: 10 · 2025: 19 · 2024: 34 · 2023: 35 · 2022: 29 · 2021: 55 · 2020: 40 · 2019: 36 · 2018: 45 · 2017: 51 · 2016: 61 · 2015: 44 · 2014: 49 · 2013: 61 · 2012: 61
FWCI: 45.76
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: The Journal of Experimental Medicine (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
PubMed Central (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
Funders: Leukemia and Lymphoma Society
Agios Pharmaceuticals
Terry Fox Foundation
Canadian Institutes of Health Research
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords: 2-hydroxyglutarate, IDH mutation, acute myeloid leukemia, alpha-ketoglutarate, NADPH-dependent reduction, gain-of-function mutations, cancer metabolism, metabolic biomarkers
MeSH terms: Catalysis, Glutarates, Humans, Isocitrate Dehydrogenase, Ketoglutaric Acids, Mutation, NADP, Recombinant Proteins, Leukemia, Myeloid, Acute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks